SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by Kennedy Capital Management LLC

Kennedy Capital Management LLC grew its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 4.9% in the fourth quarter, HoldingsChannel reports. The fund owned 78,352 shares of the company’s stock after buying an additional 3,653 shares during the period. Kennedy Capital Management LLC’s holdings in SpringWorks Therapeutics were worth $2,831,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Huntington National Bank boosted its holdings in shares of SpringWorks Therapeutics by 38.2% in the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after acquiring an additional 192 shares in the last quarter. AlphaQuest LLC lifted its position in SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new stake in SpringWorks Therapeutics in the fourth quarter worth approximately $45,000. KBC Group NV boosted its stake in SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after purchasing an additional 978 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of SpringWorks Therapeutics by 56.0% during the 4th quarter. US Bancorp DE now owns 4,336 shares of the company’s stock valued at $157,000 after purchasing an additional 1,556 shares during the period.

SpringWorks Therapeutics Trading Up 5.9 %

Shares of SWTX opened at $36.47 on Monday. The business’s 50-day moving average price is $48.63 and its 200 day moving average price is $40.10. The stock has a market capitalization of $2.73 billion, a P/E ratio of -10.48 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The firm had revenue of $61.55 million during the quarter, compared to analysts’ expectations of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. On average, research analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on SWTX. Wedbush reaffirmed an “outperform” rating and set a $81.00 target price on shares of SpringWorks Therapeutics in a research note on Thursday, February 20th. Evercore ISI raised their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Guggenheim dropped their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics currently has an average rating of “Buy” and a consensus target price of $73.20.

Insiders Place Their Bets

In related news, CEO Saqib Islam sold 48,000 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,002,502 shares of the company’s stock, valued at approximately $53,433,356.60. This represents a 4.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Pichl sold 29,750 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $54.36, for a total value of $1,617,210.00. Following the sale, the insider now owns 50,762 shares of the company’s stock, valued at $2,759,422.32. The trade was a 36.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 440,766 shares of company stock worth $24,402,956. Corporate insiders own 7.61% of the company’s stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.